Germany Drug Delivery Market Size, Share, Opportunities, And Trends By Type (Inhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), By Application (Treatment of Diseases, Research/Academic Purposes), And By Geography - Forecasts From 2025 To 2030

Germany Drug Delivery Market Size:

The German drug delivery market, valued at US$40.326 billion in 2025, is projected to grow at a CAGR of 5.43%, reaching a market size of US$52.333 billion by 2030.

Increasing research and development in the pharmaceutical sector, rising public spending, and growing chronic diseases like cardiovascular disease, cancer, diabetes, neurological disorders, etc., are significant drivers for the German drug delivery market. The growing technological development in the drug delivery market is also propelling the market expansion.

Germany Drug Delivery Market Overview & Scope:

Germany Drug Delivery market is segmented by:

• Type: German drug delivery market is segmented into Inhalation drug delivery, injectable drug delivery, nasal drug delivery, oral drug delivery, transdermal drug delivery, and others.
• Application: The market is segmented into treatment of diseases and Research/academic purposes.

Top Trends Shaping the German Drug Delivery Market:

1. Rise in demand for injectable drug delivery

• There is a rise in demand for injectable drug delivery types due to the increasing use of biologics and biosimilars for chronic diseases like cancer, diabetes, and other diseases.
• In 2020, there were a total of 605,805 new cancer cases in Germany. International Diabetes Federation estimates that by 2045, 6099 thousand people will have diabetes in the country.

2. Advancement in implantable drug delivery

• The implantable drug delivery is on a rising shift in the German drug delivery market. The market growth is due to the rising prevalence of chronic diseases, driving demand for targeted and controlled drug release.

3. Integration of artificial intelligence

• There is a shift towards integrating artificial intelligence and machine learning in drug delivery, revolutionizing patient care by enhancing data analysis and prediction.
• For instance, Genentech, a member of Roche Group, has leveraged AI and ML to redefine the drug discovery process through “The lab in a loop” mechanism, which brings generative AI to drug discovery and development.

Germany Drug Delivery Market Growth Drivers vs. Challenges:

Opportunities:

• Rising prevalence of chronic disease: The growing prevalence of chronic diseases due to the increasing consumption of alcohol and tobacco remains the primary cause of death in Germany, ensuring the development of the drug delivery market in the region. As per the European Union report on “State of Health in the EU,” one in eight deaths in 2021 in Germany is due to ischaemic heart disease. In 2020, there were a total of 605,805 new cancer cases in the nation. These data show the rising prevalence of chronic diseases, coupled with Germany's robust healthcare infrastructure. For instance, Germany spent 12.9 % of its GDP on health in 2021, significantly driving the drug delivery market.
• Rising aging population: As per the data by the European Union in its “State of Health in the EU”, Germany has higher rates of smoking, obesity, and heavy drinking than the EU averages in 2019, which poses a significant risk to the health. In 2021, more than two in five Germans aged 65 and over have more than one chronic disease, and this over-60 population is anticipated to increase to 28% share in 2050 from 22.1% in 2021, driving the healthcare market. This is raising the demand for advanced drug delivery solutions.
• Increased investment in research and development: Increasing research and development investments for drug delivery are expected to be a significant driver for the industry in the coming years. According to World Bank data, Germany spent nearly 3.14% of GDP on Research and Development expenditure in 2021. In 2021, the pharmaceutical industry invested over EUR 8.7 billion in R&D, which is more than in any European country, as per the Germany Trade & Invest, the economic development agency of the Federal Republic of Germany. Research and development in pharmaceuticals and drugs have always played an important role in developing drug delivery solutions. For instance, recently, PCI pharma services invested $365 million in infrastructure supporting the clinical assembly of products that utilized advanced drug delivery formats in the EU and US facilities, which can have a potential push to the German advanced drug delivery market.  In 2021, Novo Nordisk invested $5 million in the CHUM Foundation for an integrated research and care institute for diabetes.

Challenges:

• High cost for research and development:  The cost of research and development is high in Germany, which requires advanced facilities and technologies, acting as a major restraint for this market growth.

Germany Drug Delivery Market Competitive Landscape:

The market is consolidated, with the presence of some of the leading players such as Bayer, Boehringer Ingelheim, GlaxoSmithKline, and Novartis. They have a strong market presence in the drug delivery market. The market strategies of the players include:

• Research and Development: In January 2025, BioNxt, a company specializing in advanced drug delivery systems, accelerated R&D by establishing a new laboratory facility in Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. It will accelerate the company’s research, including in the areas of drug delivery systems.

Germany Drug Delivery Market Scope:

Report Metric	Details
Germany Drug Delivery Market Size in 2025	US$40.326 billion
Germany Drug Delivery Market Size in 2030	US$52.333 billion
Growth Rate	CAGR of 5.43%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type Application Geography
List of Major Companies in Germany Drug Delivery Market	Novartis Roche Holding AG Bayer Boehringer Ingelheim Novo Nordisk
Customization Scope	Free report customization with purchase

 

Germany Drug Delivery Market is analyzed into the following segments:

By Type

• Inhalation Drug Delivery
• Injectable Drug Delivery
• Nasal Drug Delivery
• Oral Drug Delivery
• Transdermal Drug Delivery

By Application

• Treatment of diseases
• Research/Academic purposes

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GERMANY DRUG DELIVERY MARKET BY TYPE

5.1. Introduction

5.2. Inhalation Drug Delivery

5.3. Injectable Drug Delivery

5.4. Nasal Drug Delivery

5.5. Oral Drug Delivery

5.6. Transdermal Drug Delivery

5.7. Others

6. GERMANY DRUG DELIVERY MARKET BY APPLICATION

6.1. Introduction

6.2. Unilateral

6.3. Bilateral

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

7.1. Major Players and Strategy Analysis

7.2. Market Share Analysis

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Competitive Dashboard

8. COMPANY PROFILES

8.1. Novartis

8.2. Roche Holding AG

8.3. Bayer

8.4. Boehringer Ingelheim

8.5. Novo Nordisk

8.6. Bristol Myers Squibb

8.7. GlaxoSmithKline

8.8. Scott Pharma 

9. APPENDIX

9.1. Currency 

9.2. Assumptions

9.3. Base and Forecast Years Timeline

9.4. Key benefits for the stakeholders

9.5. Research Methodology 

9.6. Abbreviations 

Novartis

Roche Holding AG

Bayer

Boehringer Ingelheim

Novo Nordisk

Bristol Myers Squibb

GlaxoSmithKline

Scott Pharma